Several trials have demonstrated that SGLT2i and GLP-1 RA can reduce major adverse cardiovascular events (MACE), death from cardiovascular diseases (CVD), and heart failure (HF) hospitalization, as well as delay the progression of chronic kidney disease (CKD) in patients at high risk of or with established atherosclerotic cardiovascular disease (ASCVD) (1–8). The gene discussed is GLP1R; the disease is atherosclerosis.